Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein. Scientists at St.
Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer retrieved 19 March 2024 from https://medicalxpress.com/news/2024-03-immunotherapy-cancer-fusion-protein-key.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Jul 28, 2021 Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Microbial signatures linked to immunotherapy response across cancersThe microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma.
続きを読む »
DNA origami vaccine DoriVac paves way for personalized cancer immunotherapyTherapeutic cancer vaccines are a form of immunotherapy in the making that could not only destroy cancer cells in patients, but keep a cancer from coming back and spreading.
続きを読む »
Circulating tumor DNA levels predict outcomes for gastroesophageal cancer treated with immunotherapyMonitoring levels of DNA shed by tumors and circulating in the bloodstream could help doctors accurately assess how gastroesophageal cancers are responding to treatment, and potentially predict future prognosis, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg–Kimmel Institute for Cancer...
続きを読む »
Q&A: Stem-immunity hubs associated with response to immunotherapyJonathan Chen, MD, Ph.D., an investigator in the Department of Pathology at Massachusetts General Hospital, and Nir Hacohen, Ph.D.
続きを読む »
The Future of Food Allergy Management: New Technologies and TreatmentsFood allergies, triggered by specific allergens, can lead to severe reactions like anaphylaxis. However, innovative treatments such as immunotherapy are revolutionizing allergy management.
続きを読む »
Protein 'brake' could help develop new cancer treatmentsSome cancerous tumors hijack proteins that act as 'brakes' on our immune system and use them to form a sort of shield against immune recognition. Immunotherapy treatments have been created that turn off these 'brakes' and allow our body to attack foreign-looking cancer cells.
続きを読む »